Genmab (CPSE:GMAB) Lifts 2026 Outlook As Pipeline Progress Keeps Undervalued Narrative Alive
Genmab guidance change and recent earnings at a glance
Genmab (CPSE:GMAB) has raised its 2026 revenue outlook following second quarter results, alongside regulatory progress in Europe and positive Phase III data for key pipeline drugs that broaden its revenue base beyond DARZALEX.
See our latest analysis for Genmab.
Genmab’s near term momentum has picked up, with a 6.5% 1 day share price return and 20.5% 90 day share price return, while the 1 year total shareholder return of 44.7% contrasts with weaker 3 and 5 year total shareholder returns.
If Genmab’s recent move has you rethinking healthcare and biotech exposure, this is a good moment to broaden your watchlist with 130 healthcare AI stocks.
Genmab’s pipeline progress and upgraded 2026 revenue guidance point to a stronger business story. After the recent share price jump, the key question is whether the stock still offers fair value or already reflects that optimism.
Most Popular Narrative: 16.4% Undervalued
The most followed narrative on Genmab compares a fair value of DKK2,392.08 to the last close of DKK1,999 and presents the stock as trading at a clear discount, with that gap tied closely to how well the pipeline can offset future pressure on partnered royalties.
Strong late-stage pipeline progress, including positive Phase III results for epcoritamab (EPKINLY) and expansion of Rina-S programs, positions Genmab to benefit from the growing global burden of cancer and rising demand for innovative biologic therapies, supporting significant future revenue and earnings growth.
Want to see the full playbook behind that valuation gap? The core narrative focuses on compound revenue growth, rising margins and a lower future earnings multiple than many investors might expect.
Result: Fair Value of DKK2,392.08 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Genmab’s story still depends on smooth execution, since any setback in Epkinly trials or faster than expected DARZALEX royalty pressure could quickly challenge this bullish narrative.
Find out about the key risks to this Genmab narrative.
Another View on Genmab’s Valuation
The first narrative leans heavily on future earnings and price targets to argue that Genmab is undervalued. A different angle looks at the current P/E of 23.4x versus an estimated fair ratio of 23.8x and peer averages of 16.2x and 22.6x, which points to much less obvious upside. Which lens do you trust more?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With both risks and rewards in play for Genmab, it makes sense to review the numbers yourself and decide quickly where you stand. To get a clear view of both sides of the story, start with the 2 key rewards and 3 important warning signs.
Looking for more investment ideas beyond Genmab?
If Genmab has sharpened your interest in healthcare and growth stories, use this moment to widen your opportunity set and stress test your portfolio against fresh ideas.
- Spot potential standouts early by scanning 219 elite penny stocks with strong financials, which pair smaller market caps with financial markers that may be stronger than many investors expect.
- Strengthen your core holdings by reviewing companies in the solid balance sheet and fundamentals stocks screener (423 results), which combine healthier finances with more resilient business profiles.
- Stay ahead of the crowd by searching the screener containing 553 high quality undiscovered gems before broader attention and pricing fully catch up.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com